Adagio Therapeutics (ADGI)
US Market

Adagio Therapeutics (ADGI) Stock Price & Analysis


ADGI Stock Chart & Stats

Day’s Range$4.4 - $4.74
52-Week Range― - ―
Previous Close$4.6
Average Volume (3M)N/A
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding108,830,525
10 Day Avg. Volume475,308
30 Day Avg. Volume646,245
Standard Deviation0.38
Financial Highlights & Ratios
Price to Book (P/B)1.15
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Adagio Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Adagio Therapeutics’s market cap?
Currently, no data Available
When is Adagio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adagio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Adagio Therapeutics overvalued?
According to Wall Street analysts Adagio Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Adagio Therapeutics pay dividends?
    Adagio Therapeutics does not currently pay dividends.
    What is Adagio Therapeutics’s EPS estimate?
    Adagio Therapeutics’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Adagio Therapeutics have?
    Currently, no data Available
    What happened to Adagio Therapeutics’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Adagio Therapeutics?
    Among the largest hedge funds holding Adagio Therapeutics’s share is Slate Path Capital LP. It holds Adagio Therapeutics’s shares valued at 12M.


      Adagio Therapeutics Stock Smart Score

      The Adagio Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
      Learn more about TipRanks Smart Score

      Company Description

      Adagio Therapeutics

      Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.


      Forecast EPS vs Actual EPS

      Currently, no data available
      Please return soon. This page is being updated.

      Similar Stocks
      Price & Change
      Gilead Sciences
      Vertex Pharmaceuticals

      Popular Stocks

      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis